Bristol-Myers Squibb and AstraZeneca announced that, following the completion of Bristol-Myers Squibb’s acquisition of Amylin, the companies will enter into collaboration arrangements, regarding the development and commercialization of Amylin’s product line.
Following Bristol-Myers Squibb’s acquisition of Amylin, AstraZeneca will make a payment to Amylin, as a wholly owned subsidiary of Bristol-Myers Squibb, in the amount of approximately $3.4 billion in cash.
Profits and losses arising from the collaboration will be shared equally. In addition, AstraZeneca has the option to establish equal governance rights over key strategic and financial decisions regarding the collaboration, upon the payment to Bristol-Myers Squibb of an additional $135 million.
Find out more by clicking the link below:
